266 results about "Psychiatric Disease" patented technology

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg or less of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg or less of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Dosage forms, drug delivery systems, and methods related to dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, such as bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, such as bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

Compositions comprising microalgal extracellular vesicles (MEVs) formulated for intranasal delivery are provided, whereby upon intranasal administration, the MEVs are transported by a specific route, to specific regions in the brain via the olfactory nerve after intranasal administration, and to interconnected brain regions through the lateral olfactory tract (LOT). The MEVs are transported via neuronal axonal transport. The MEVs have the ability to cross synapses including: (i) synapses between olfactory sensory neurons (OSNs) and mitral / tufted neurons; (ii) synapses between mitral / tufted neurons and local neurons in multiple brain regions colonized by the lateral olfactory tract (LOT); and (iii) synapses between neurons in brain regions colonized by the LOT and neurons from the frontal cortex, hippocampus, thalamus, and hypothalamus. The compositions contain extracellular vesicles (MEVs) from microalgae loaded with bioactive cargo for the treatment, detection, diagnosis, or monitoring of diseases, disorders, or conditions of or involving the brain, particularly neuronal delivery of the cargo. The compositions and methods have multiple applications as therapeutic and diagnostic agents for the treatment, diagnosis, and monitoring of diseases, disorders, or conditions of or involving the brain. The compositions can be used in methods and uses for the treatment of cancers involving the brain, and can be used, for example, to deliver therapeutic agents for psychiatric diseases, disorders, conditions, and to deliver therapeutic agents for neurodegenerative diseases, disorders, and conditions.

The invention relates to psychoactive medicines including methylone, 2C-B, MBDB, their respective salts, metabolites, isomers, enantiomers, solvates, isotopologues and isotopomers, polymorphs, prodrugs and analogs (2C-series and cathinones); their preparation, formulations, intermediates, routes of administration, dosing and schedule for medical uses for psychiatric and neurological conditions and disorders.

The disclosure provides new transmucosal and subcutaneous pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or 1-(4-fluoro-phenyl)-4-((6bR,10aS)-2,2-d2-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or comprising -(4-fluoro-phenyl)-4-((6bR,10aS)-1,1,2,2-d4-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, in free base, co-crystal or salt form, together with methods of making and using them.

Provided are compositions containing extracellular vesicles from microalgae (MEVs) that are loaded with bioactive cargo. The MEVs are formulated and administered by a variety of routes of administration and have a variety of applications as therapeutics, including as vaccines, as anti-cancer therapeutics, as therapeutics for psychiatric diseases, disorders, and conditions, and as diagnostics, and other such uses.

The invention discloses a temperature control type self-restraint infusion nursing device for psychiatric patients, and belongs to the technical field of restraint devices.The temperature control type self-restraint infusion nursing device comprises a restraint sleeve, the restraint sleeve comprises two semi-cylinders which are rotationally connected with each other, and clamping pieces are arranged on the inner walls of the semi-cylinders and comprise a plurality of longitudinal partition plates arranged on the inner walls of the semi-cylinders; transverse partition plates are further arranged in the middles of the inner walls of the half barrels, blocking areas are reserved between the longitudinal partition plates and the transverse partition plates, expansion air bags are installed in the blocking areas and higher than the longitudinal partition plates and the transverse partition plates, and ventilation channels are formed in the spaces, partitioned by the partition plates, between the expansion air bags. By arranging the expansion air bags and the ventilation channels, air circulation can be kept through the ventilation channels among the expansion air bags while the arms of a patient are squeezed by the expansion air bags, the discomfort caused by the fact that the air bags completely cover and press the arms is relieved, and the conflict psychology of the patient is reduced.

Dosage forms, drug delivery systems, and methods related to dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, such as bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

The invention provides a mental disease classification method and system based on an individual difference structure covariant network and machine learning, and belongs to the field of mental disease classification. The problem of classification performance bottleneck caused by heterogeneity of mental diseases in the prior art is solved. The method comprises the following steps: acquiring a structural magnetic resonance T1 weighted image, and preprocessing the image; performing brain region segmentation on the pre-processed T1 image based on an AAL brain map, and extracting the gray matter volume of each brain region; constructing an IDSCN network by calculating the Pearson's correlation coefficient of the brain grey matter volume of the paired brain regions; calculating the area under a node topological attribute curve of the IDSCN network; screening node attribute indexes with statistical differences between the patient group and the healthy control group through double-sample t test; and taking the screened node attribute indexes as feature vectors, and inputting the feature vectors into a support vector machine classification model for disease classification. The method is mainly used in the medical image processing field.

A dosage form of lacosamide and a pharmaceutical dosage form thereof is disclosed. The dosage form includes an extended release portion and optionally an immediate release portion. Also provided are methods of providing extended release of lacosamide and treatment of: neurological or psychiatric disease or condition.

A method and apparatus for use as part of diagnostic analysis of the psychiatric or neurological health of a patient based on use of a normative database of fMRI data results and cognitive task results for a population of prior patients. Embodiments propose to acquire fMRI data of a particular set of one or more regions of the brain of a patient while the patient is performing a cognitive task, and to record at the same time results of the patient's performance in the cognitive task. A combination of both the cognitive task results and the fMRI data for the brain regions is used to provide an indicator as to a cognitive health status of the patient. More particularly, a normative database of fMRI data results and cognitive task results for a population of patients is used as a reference. This may store results both for healthy patients and pathological patients, to provide a normal and abnormal reference.

The invention discloses a temperature-controlled self-constrained transfusion nursing device for psychiatric patients, and belongs to the technical field of medical auxiliary instruments, the temperature-controlled self-constrained transfusion nursing device comprises a constraint sleeve, and the constraint sleeve comprises a left sheath and a right sheath which are hinged to each other; a needle head protection mechanism for protecting the needle head is arranged between the left sheath and the right sheath and is in sliding fit with the left sheath and the right sheath; an air bag massage mechanism and a vibration massage mechanism which are used for relieving arms are arranged in the left protective sleeve and the right protective sleeve, the vibration massage mechanism is located in the air bag massage mechanism, and the vibration massage mechanism is in sliding fit with the air bag massage mechanism; and the left sheath is provided with an infusion heating mechanism for heating liquid. According to the invention, the arm of a psychopath can be periodically massaged when the psychopath is transfused, so that the blood circulation of the arm is promoted, and the muscle fatigue feeling is relieved.

The invention relates to the technical field of psychiatric disease diagnosis, and discloses a defective schizophrenia prediction and analysis system based on multi-modal brain network characteristics, which comprises an image data acquisition module, an image data processing module, a deep learning model module and a prediction module which are connected in sequence, the image data acquisition module acquires a brain MRI image; the image data processing module carries out cortical and subcortical reconstruction on the brain MRI image to obtain a model input index; the deep learning model module performs training by using a training data set composed of a plurality of brain MRI images and defective schizophrenia diagnosis results thereof to obtain a target prediction model; and the prediction module inputs the real-time brain MRI image into the target prediction model to obtain a prediction result. According to the method, the multi-dimensional brain structure image features are integrated, diagnosis information contained in brain region changes is fully mined, prediction results of defective schizophrenia and non-defective schizophrenia are improved, and a more comprehensive biological basis is provided for clinical diagnosis.

This disclosure relates to, inter alia, certain compounds, compositions, and pharmaceutical compositions thereof, that modulate the activity of the transporter protein vesicular monoamine transporter- 2 (VMAT2) and are directed to methods useful in the treatment of transporter protein vesicular monoamine transporter-2 mediated disorders, such as, neurological or psychiatric disease or disorders, including but not limited to, hyperkinetic movement disorders (e.g., tardive dyskinesia, Tourette's syndrome, Huntington's disease, tics, ataxia, chorea (such as, chorea associated with Huntington's disease), dystonia, hemifacial spasm, myoclonus, restless leg syndrome, and tremors). The disclosure further relates to synthetic methods and intermediates useful in the preparation of compounds.

Systems and methods for the identification of auto-antibodies associated with central nervous system or psychiatric disease or disorders. Also disclosed herein are methods of treating central nervous system or psychiatric disease or disorders associated with auto-antibodies.

The present disclosure relates to administering in certain patient populations a combination of: 1) about 100 to 110 mg, about 104 to 106 mg, or about 105 mg or less of bupropion hydrochloride or a molar equivalent of bupropion in the form of a free base or in the form of another salt; and 2) dextromethorphan hydrobromide or a molar equivalent of dextromethorphan in the form of a free base or another salt, in the amount of about 40 to 50 mg, about 44 to 46 mg, or about 45 mg or less, the patient populations such as patients suffering from moderate renal injury, patients receiving companion strong CYP2D6 inhibitors, patients known as CYP2D6 weak metabolites, patients in need of NMDA antagonists that do not cause dissociation, and patients at risk of QT prolongation.

There is provided a computer implemented method of diagnosing a medical state associated with a neuro-psychiatric disorder in a subject, comprising: receiving a plurality of EEG datasets, each respective EEG dataset from a respective EEG electrode of a plurality of EEG electrodes monitoring a head of the subject, clustering the plurality of EEG datasets into a plurality of clusters, computing a p-adic representation of the plurality of clusters, extracting a quantum potential value from p-adic representation of the plurality of clusters, and diagnosing the medical state associated with the neuro-psychiatric disorder according to the quantum potential relative to a threshold that separates between presence of the medical state and non-presence of the medical state.

Disclosed herein are tricyclic compounds, including pyrimido[4′,5′:4,5]thieno[2,3-c]pyridazine-8-amine, pyrido[3′,2′:4,5]thieno[3,2-d]pyrimidine-4-amine, pyrazino[2′,3′:4,5]thieno[3,2-d]pyrimidin-4-amine, pyrido[3′,2′:4,5]furo[3,2-d]pyrimidin-4-amine, and pyrimido[4′,5′:4,5]furo[2,3-c]pyridazin-8-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.

1. Name of the Design Product: Restraint Chair (for the Mentally Ill). 2. Use of the Design Product: For restraining the mentally ill. 3. Design Key Points of the Design Product: Lies in the shape. 4. Picture or Photograph that Best Illustrates the Design Key Points: Perspective View 1.

This specification discloses systems and computer-implemented evaluation methods, including systems and methods for assigning individuals to groups participating in clinical studies on mental illness, systems and methods for determining whether an individual is likely to suffer from a mental illness and what type of mental illness the individual is likely to suffer from; and systems and methods for recommending treatments for individuals suffering from mental illness. All disclosed systems and computer-implemented evaluation methods use a non-invasive computing device-based test that uses a graphical user interface to measure an individual's latent inhibition response to calculate a latent inhibition score and evaluate working memory. The latent inhibition score determines whether an individual exhibits a weakened latent inhibition response, a normal latent inhibition response, or an enhanced latent inhibition response.

The patent document discloses a dosage form featuring a unique combination of extended-release and immediate-release components of the active ingredient. This dosage form allows for high drug loading, enabling once-daily administration while providing a sustained window of effective treatment with reduced fluctuations in drug concentration. The document also discloses a method for treating neurological or psychiatric diseases or conditions in a subject.

The present disclosure provides a method of treating or ameliorating a mental health disorder or a central nervous system disorder in a subject in need thereof, comprising administering to the subject a composition comprising a crystalline form of psilocin and psilocybin, wherein the crystalline form is co-crystal form A of psilocin and psilocybin and an atypical antipsychotic.

The present invention relates to compounds having a fused, substituted tricyclic scaffold and stereo-isomeric forms, solvates, hydrates and / or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these substituted tricyclic derivatives together with pharmaceutically acceptable carrier, excipient and / or diluents. Said substituted tricyclic derivatives have been identified as especially potent ligands of FK506 binding proteins (FKBPs), especially human FKBP12, FKBP12.6, FKBP51 and FKBP52 or bacterial homologs like LpMip, CtMip, CpMip, NgMip, KpMip, BpMip, TcMip, EcFKLB, EcFKPA, PaFKLB, PaFKPA, AbFKLB, AbFKPA, and are useful for treatment of diseases such as psychiatric, metabolic, infective, neurological and haematological disorders as well as pain and cancers and as anti-inflammatory drugs. Said substituted tricyclic derivatives may further be used as agents for inducing protein-protein interactions (PPIs) acting as molecular glues.